Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences, Inc. (NASDAQ: ENVB) is a biotechnology company developing small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. The ENVB news feed on Stock Titan aggregates company-issued press releases and other public updates so readers can follow how Enveric describes the progress of its pipeline, intellectual property estate, and capital markets activity.
Recent news from Enveric highlights several recurring themes. The company frequently reports on patent issuances and notices of allowance from the United States Patent and Trademark Office, including patents covering fused heterocyclic mescaline derivatives and N‑heterocycle substituted tryptamine derivatives within its EVM301 and EVM401 series. These announcements emphasize Enveric’s efforts to expand its portfolio of neuroplastogenic, non-hallucinogenic molecules and to strengthen composition of matter protection for potential treatments of neuropsychiatric and addiction disorders.
Another key category of ENVB news involves pipeline and preclinical development for the lead candidate EB‑003. Company updates have discussed preclinical models in post-traumatic stress disorder, dose range finding studies, chemistry and manufacturing work, and interactions with the U.S. Food and Drug Administration related to a planned Investigational New Drug submission. These items provide insight into how Enveric portrays the advancement of EB‑003 toward potential first-in-human studies.
Enveric also issues news related to financing and listing matters, such as warrant exercise inducement transactions, gross proceeds from warrant exercises, and actions taken in connection with Nasdaq listing requirements, including a reverse stock split. For investors and observers, these releases give context on how the company funds its operations and addresses exchange compliance.
By reviewing ENVB news on Stock Titan, readers can monitor Enveric’s own descriptions of its scientific progress, patent estate, financing transactions, and corporate developments over time. Investors who follow early-stage biotechnology companies may choose to consult these updates alongside the company’s SEC filings for a fuller view of the risks and plans Enveric outlines in its public communications.
Enveric Biosciences (NASDAQ: ENVB) has appointed Dr. Bob Dagher as Chief Medical Officer, effective immediately. With over 20 years of clinical development experience in neurology and psychiatry, Dr. Dagher aims to advance the company's psychedelic-derived and synthetic cannabinoid treatments. His prior roles include Chief Medical Officer at WCG MedAvante-ProPhase and Cadent Therapeutics. Dr. Robert Wilkins, the previous CMO, stepped down on November 29, 2021. CEO Joseph Tucker emphasizes the importance of Dr. Dagher's expertise in driving Enveric's drug development programs.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on mental health and oncology, announced that Dr. Joseph Tucker, CEO, will present at the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021. The presentation will be available on-demand starting at 7:00 a.m. ET. This conference aims to showcase innovative treatments derived from psychedelics and synthetic cannabinoids, with Enveric's research targeting conditions like cancer-related distress and PTSD. Attendees can register to watch and schedule one-on-one meetings with management.
Enveric Biosciences (NASDAQ: ENVB) announced promising preclinical results for its product EV102, aimed at treating radiodermatitis in cancer patients. In rodent models, EV102 demonstrated a nearly 50% reduction in skin redness and overall dermatitis severity, as well as a decrease in symptom duration. These findings are critical as radiodermatitis affects up to 95% of radiation therapy patients. The company plans to advance EV102 to a Phase I clinical study in the second half of 2022, underpinning its commitment to improving the quality of life for cancer patients.
Enveric Biosciences (NASDAQ: ENVB) announced its inclusion in the AdvisorShares Psychedelics ETF (PSIL), which targets biotech and pharma companies focusing on psychedelic treatments. This milestone is seen as a validation of Enveric's innovative platform for developing psychedelic and cannabinoid medicines aimed at addressing mental health issues and oncology treatments. CEO Joseph Tucker emphasized that this recognition will enhance their visibility within the investment community.
Enveric Biosciences (NASDAQ: ENVB) has announced that CEO Dr. Joseph Tucker will speak at the Microdose Presents Wonderland conference in Miami on November 8-9, 2021. Dr. Tucker is scheduled to participate in the Next-Generation Psychedelics panel on November 8 at 3:10 p.m. ET. Enveric is focused on developing innovative treatments for mental health and oncology using psychedelic-derived molecules and synthetic cannabinoids.
For details on attendance and meetings, interested parties can contact Microdose representatives or email KCSA Strategic Communications.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focusing on mental health and oncology treatments, announced that Dr. Joseph Tucker, CEO, will participate in two upcoming conferences: the A.G.P. Biotech & Specialty Pharma Conference on October 13, 2021, and the KCSA Psychedelics Investor Conference from October 13-14, 2021. Dr. Tucker will present live on October 13 at 11:30 a.m. ET. Interested parties can register for the events through provided links. Enveric is developing innovative treatments using psychedelic-derived molecules and synthetic cannabinoids.
Enveric Biosciences (NASDAQ: ENVB) has announced that its AI tool, PsyAI, has successfully identified potential psychedelic drug candidates from its database of 500 compounds. This technology enhances the drug discovery process for challenging mental health issues, including cancer-related distress and PTSD. Using machine-learning models, PsyAI predicts the drug potential and helps categorize compounds, which could streamline the development of viable drug candidates. Enveric aims to improve treatment options for patients suffering from debilitating conditions.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on mental health and oncology treatments, announced participation in two investor conferences. CEO Dr. Joseph Tucker will take part in the Maxim's Advances in Mental Health Virtual Conference on September 22 at 10:00 a.m. ET, discussing 'Next Gen Psychedelics: Novel Chemical Entities'. He will also present at the Benzinga's Healthcare Small Cap Virtual Conference on September 30 at 3:40 p.m. ET. Enveric aims to address mental health issues using psychedelic-derived molecules and synthetic cannabinoids.
Enveric Biosciences (NASDAQ: ENVB) has successfully closed its acquisition of MagicMed Industries, a biotechnology firm focused on developing psychedelic molecules for mental health treatments. This all-stock transaction gives Enveric access to a novel library of psychedelic derivatives, enhancing its drug development pipeline targeting conditions like cancer-related distress, PTSD, and anxiety. Enveric issued approximately 9.95 million shares to MagicMed shareholders, with existing Enveric shareholders retaining 68.3% ownership. Dr. Joseph Tucker, former CEO of MagicMed, will lead Enveric as its new CEO.
Enveric Biosciences (NASDAQ: ENVB) announced that Dr. Joseph Tucker, CEO of MagicMed Industries, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 and the Virtual Gravitas Health Reimagined Investor Day on September 16. Enveric is developing cannabinoid medicines aimed at improving the quality of life for cancer patients, with an annual meeting scheduled for September 14. The upcoming presentations underline the company's commitment to innovation in oncology therapy through the acquisition of MagicMed.